Zinc supplementation partially prevents renal pathological changes in diabetic rats

Journal of Nutritional Biochemistry

Volumn 21, Issue 3, 2010, Pages 237-246

  Tang, Yunan ^a,b   Yang, Qin ^c   Lu, Jiayin ^d   Zhang, Xiaolin ^c   Suen, Di ^c   Tan, Yi ^a,b   Jin, Litai ^a   Xiao, Jian ^a   Xie, Rujia ^c   Rane, Madhavi ^a,b   Li, Xiaokun ^a   Cai, Lu ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

Author keywords

CTGF; Diabetic nephropathy; Metallothionein; Renal tubular cells; Zinc

Indexed keywords

CADMIUM; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; METALLOTHIONEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; ZINC SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; INFLAMMATION; KIDNEY TUBULE CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; UPREGULATION; VITAMIN SUPPLEMENTATION;

ANIMALS; BLOOD GLUCOSE; CELL LINE; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; KIDNEY; KIDNEY TUBULES, PROXIMAL; LIPID PEROXIDATION; MALE; METALLOTHIONEIN; ORGAN SPECIFICITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ISOFORMS; PROTEINURIA; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; SUPEROXIDE DISMUTASE; ZINC;

RATTUS;

EID: 76749154985     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2008.12.010     Document Type: Article

References (59)

1. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
2. Ahmad F.K., He Z., and King G.L. Molecular targets of diabetic cardiovascular complications. Curr Drug Targets 6 (2005) 487-494
3. Jay D., Hitomi H., and Griendling K.K. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40 (2006) 183-192
4. Brandao-Neto J., Silva C.A., Shuhama T., Silva J.A., and Oba L. Renal handling of zinc in insulin-dependent diabetes mellitus patients. Biometals 14 (2001) 75-80
5. Batista M.N., Cuppari L., de Fatima Campos Pedrosa L., Almeida M.G., de Almeida J.B., de Medeiros A.C., et al. Effect of end-stage renal disease and diabetes on zinc and copper status. Biol Trace Elem Res 112 (2006) 1-12
6. Soinio M., Marniemi J., Laakso M., Pyorala K., Lehto S., and Ronnemaa T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 30 (2007) 523-528
7. Song Y., Wang J., Li X.K., and Cai L. Zinc and the diabetic heart. Biometals 18 (2005) 325-332
8. Alscher D.M., Braun N., Biegger D., Stuelten C., Gawronski K., Murdter T.E., et al. Induction of metallothionein in proximal tubular cells by zinc and its potential as an endogenous antioxidant. Kidney Blood Press Res 28 (2005) 127-133
9. Wang J., Song Y., Elsherif L., Song Z., Zhou G., Prabhu S.D., et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113 (2006) 544-554
10. Nordberg G.F., Goyer R., and Nordberg M. Comparative toxicity of cadmium-metallothionein and cadmium chloride on mouse kidney. Arch Pathol 99 (1975) 192-197
11. Cacini W., and Singh Y. Renal metallothionein and platinum levels in diabetic and nondiabetic rats injected with cisplatin. Proc Soc Exp Biol Med 197 (1991) 285-289
12. Jin T., Nordberg G.F., Sehlin J., Leffler P., and Wu J. The susceptibility of spontaneously diabetic mice to cadmium-metallothionein nephrotoxicity. Toxicology 89 (1994) 81-90
13. Cai L., Chen S., Evans T., Cherian M.G., and Chakrabarti S. Endothelin-1-mediated alteration of metallothionein and trace metals in the liver and kidneys of chronically diabetic rats. Int J Exp Diabetes Res 3 (2002) 193-198
14. Zalups R.K., and Cherian M.G. Renal metallothionein metabolism after a reduction of renal mass. II. Effect of zinc pretreatment on the renal toxicity and intrarenal accumulation of inorganic mercury. Toxicology 71 (1992) 103-117
15. Sharma R., Sharma M., Datta P.K., and Savin V.J. Induction of metallothionein-I protects glomeruli from superoxide-mediated increase in albumin permeability. Exp Biol Med (Maywood) 227 (2002) 26-31
16. Iqbal M., Noor R., Mizuno R., and Okada S. Protective role of zinc-metallothionein (Zn-MT) in iron nitrilotriacetate (Fe-NTA)-induced renal oxidative damage. Redox Rep 8 (2003) 163-167
17. Song Y., Li C., and Cai L. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 76 (2004) 66-75
18. Adamczak M., Gross M.L., Krtil J., Koch A., Tyralla K., Amann K., et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14 (2003) 2833-2842
19. Racusen L.C., Monteil C., Sgrignoli A., Lucskay M., Marouillat S., Rhim J.G., et al. Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 129 (1997) 318-329
20. Cai L., Li W., Wang G., Guo L., Jiang Y., and Kang Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51 (2002) 1938-1948
21. Nakagawa T., Lan H.Y., Glushakova O., Zhu H.J., Kang D.H., Schreiner G.F., et al. Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts. J Am Soc Nephrol 16 (2005) 899-904
22. Sakai N., Wada T., Furuichi K., Iwata Y., Yoshimoto K., Kitagawa K., et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 45 (2005) 54-65
23. Sarkozi R., Miller B., Pollack V., Feifel E., Mayer G., Sorokin A., et al. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. J Cell Physiol 211 (2007) 88-100
24. Eddy A.A., and Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17 (2006) 2999-3012
25. Lee H.B., and Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton) 10 Suppl (2005) S11-S13
26. Lyon C.J., and Hsueh W.A. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115 Suppl 8A (2003) 62S-68S
27. Rerolle J.P., Hertig A., Nguyen G., Sraer J.D., and Rondeau E.P. Plasminogen activator inhibitor Type 1 is a potential target in renal fibrogenesis. Kidney Int 58 (2000) 1841-1850
28. Zhou G., Li C., and Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 165 (2004) 2033-2043
29. Okada H., Kikuta T., Kobayashi T., Inoue T., Kanno Y., Takigawa M., et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 16 (2005) 133-143
30. Guha M., Xu Z.G., Tung D., Lanting L., and Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of Type 1 and Type 2 diabetes. Faseb J (2007)
31. Forbes J.M., Coughlan M.T., and Cooper M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57 (2008) 1446-1454
32. Cai L., Wang J., Li Y., Sun X., Wang L., Zhou Z., et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 54 (2005) 1829-1837
33. Cai L. Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications. Curr Med Chem 14 (2007) 2193-2203
34. Cai L., and Cherian M.G. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium-metallothioneins. Toxicol Lett 136 (2003) 193-198
35. Cai L., Klein J.B., and Kang Y.J. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem 275 (2000) 38957-38960
36. Song Y., Wang J., Li Y., Du Y., Arteel G.E., Saari J.T., et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol 167 (2005) 17-26
37. Liang Q., Carlson E.C., Donthi R.V., Kralik P.M., Shen X., and Epstein P.N. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51 (2002) 174-181
38. Cheng B., Liu H.W., Fu X.B., Sun T.Z., and Sheng Z.Y. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci 45 (2007) 193-201
39. Ceylan-Isik A.F., LaCour K.H., and Ren J. Sex difference in cardiomyocyte function in normal and metallothionein transgenic mice: the effect of diabetes mellitus. J Appl Physiol 100 (2006) 1638-1646
40. Cai L., Wang Y., Zhou G., Chen T., Song Y., Li X., et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48 (2006) 1688-1697
41. DeRubertis F.R., Craven P.A., and Melhem M.F. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism 56 (2007) 1256-1264
42. Mollsten A., Marklund S.L., Wessman M., Svensson M., Forsblom C., Parkkonen M., et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 56 (2007) 265-269
43. Craven P.A., Melhem M.F., Phillips S.L., and DeRubertis F.R. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50 (2001) 2114-2125
44. Brezniceanu M.L., Liu F., Wei C.C., Tran S., Sachetelli S., Zhang S.L., et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 71 (2007) 912-923
45. Kedziora-Kornatowska K., Szram S., Kornatowski T., Szadujkis-Szadurski L., Kedziora J., and Bartosz G. Effect of vitamin E and vitamin C supplementation on antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Nephron Exp Nephrol 95 (2003) e134-e143
46. Huang J.S., Chuang L.Y., Guh J.Y., Huang Y.J., and Hsu M.S. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol (2007)
47. Anderson R.A., Roussel A.M., Zouari N., Mahjoub S., Matheau J.M., and Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with Type 2 diabetes mellitus. J Am Coll Nutr 20 (2001) 212-218
48. Minami T., Ichii M., Okazaki Y., Kubo M., Kadota E., Inoue T., et al. Renal changes of streptozotocin-induced diabetic rats fed a low-zinc diet. Ren Fail 17 (1995) 349-363
49. Cai L., Cherian M.G., Iskander S., Leblanc M., and Hammond R.R. Metallothionein induction in human CNS in vitro: neuroprotection from ionizing radiation. Int J Radiat Biol 76 (2000) 1009-1017
50. Cai L., Iskander S., Cherian M.G., and Hammond R.R. Zinc- or cadmium-pre-induced metallothionein protects human central nervous system cells and astrocytes from radiation-induced apoptosis. Toxicol Lett 146 (2004) 217-226
51. Zheng S., Carlson E.C., Yang L., Kralik P.M., Huang Y., and Epstein P.N. Podocyte-Specific Overexpression of the Antioxidant Metallothionein Reduces Diabetic Nephropathy. J Am Soc Nephrol (2008)
52. Devirgiliis C., Zalewski P.D., Perozzi G., and Murgia C. Zinc fluxes and zinc transporter genes in chronic diseases. Mutat Res 622 (2007) 84-93
53. Maret W. A role for metallothionein in the pathogenesis of diabetes and its cardiovascular complications. Mol Genet Metab 94 (2008) 1-3
54. Quraishi I., Collins S., Pestaner J.P., Harris T., and Bagasra O. Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus. Med Hypotheses 65 (2005) 887-892
55. Farvid M.S., Jalali M., Siassi F., and Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in Type 2 diabetes. Diabetes Care 28 (2005) 2458-2464
56. Kadhim H.M., Ismail S.H., Hussein K.I., Bakir I.H., Sahib A.S., Khalaf B.H., et al. Effects of melatonin and zinc on lipid profile and renal function in Type 2 diabetic patients poorly controlled with metformin. J Pineal Res 41 (2006) 189-193
57. Parham M., Amini M., Aminorroaya A., and Heidarian E. Effect of zinc supplementation on microalbuminuria in patients with Type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial. Rev Diabet Stud 5 (2008) 102-109
58. Al-Maroof R.A., and Al-Sharbatti S.S. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of Type 2 diabetics. Saudi Med J 27 (2006) 344-350
59. Gupta R., Garg V.K., Mathur D.K., and Goyal R.K. Oral zinc therapy in diabetic neuropathy. J Assoc Physicians India 46 (1998) 939-942